ANI Pharmaceuticals (NASDAQ:ANIP) Raised to Sell at BidaskClub

BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong sell rating to a sell rating in a research report report published on Saturday, BidAskClub reports.

ANIP has been the subject of a number of other research reports. Zacks Investment Research cut shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, May 27th. Cantor Fitzgerald lowered shares of ANI Pharmaceuticals from an overweight rating to a neutral rating and decreased their price objective for the stock from $78.00 to $40.00 in a report on Thursday, May 7th. ValuEngine lowered shares of ANI Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, April 30th. Guggenheim decreased their price objective on shares of ANI Pharmaceuticals from $62.00 to $58.00 and set a buy rating on the stock in a report on Thursday, April 30th. Finally, Raymond James decreased their price objective on shares of ANI Pharmaceuticals from $65.00 to $49.00 and set an outperform rating on the stock in a report on Friday, May 8th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $46.50.

Shares of ANI Pharmaceuticals stock opened at $32.34 on Friday. The stock has a market capitalization of $368.87 million, a P/E ratio of -215.59 and a beta of 1.46. The company has a quick ratio of 1.33, a current ratio of 2.00 and a debt-to-equity ratio of 0.93. The company has a 50-day simple moving average of $31.32 and a 200 day simple moving average of $46.70. ANI Pharmaceuticals has a 12-month low of $28.28 and a 12-month high of $86.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.15. The business had revenue of $49.77 million during the quarter, compared to analysts’ expectations of $49.40 million. ANI Pharmaceuticals had a negative net margin of 0.67% and a positive return on equity of 23.92%. On average, equities analysts anticipate that ANI Pharmaceuticals will post 3.84 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp boosted its stake in shares of ANI Pharmaceuticals by 5.0% in the 1st quarter. State Street Corp now owns 325,353 shares of the specialty pharmaceutical company’s stock valued at $13,255,000 after purchasing an additional 15,490 shares during the last quarter. Investment Counselors of Maryland LLC boosted its stake in shares of ANI Pharmaceuticals by 1.8% in the 4th quarter. Investment Counselors of Maryland LLC now owns 284,334 shares of the specialty pharmaceutical company’s stock valued at $17,535,000 after purchasing an additional 4,974 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 23.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 278,730 shares of the specialty pharmaceutical company’s stock valued at $17,189,000 after purchasing an additional 53,577 shares during the last quarter. First Manhattan Co. boosted its stake in shares of ANI Pharmaceuticals by 6.5% in the 1st quarter. First Manhattan Co. now owns 269,876 shares of the specialty pharmaceutical company’s stock valued at $10,994,000 after purchasing an additional 16,403 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. boosted its stake in shares of ANI Pharmaceuticals by 28.3% in the 1st quarter. Global Alpha Capital Management Ltd. now owns 217,746 shares of the specialty pharmaceutical company’s stock valued at $8,871,000 after purchasing an additional 48,000 shares during the last quarter. 65.65% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: Backdoor Roth IRA Conversion and Strategy

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.